Cannabidiol is under clinical development by Sapient Therapeutics and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cannabidiol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cannabidiol overview

Cannabidiol (SAP-021) is under development for the treatment of epilepsy, schizophrenia and psychosis. The drug candidate is administered through oral route in the form of tablet and acts by targeting cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2). It is being developed based on Veloxe technology platform.

Sapient Therapeutics overview

Sapient Therapeutics a biopharmaceutical company that uses Phase 1 clinical trials for discovery of neuroscience drug development discovery with Veloxe technology platform. The company is headquartered in London, Greater London, the UK.

For a complete picture of Cannabidiol’s drug-specific PTSR and LoA scores, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.